Company Overview - Real Bio Technology Co., Ltd. has submitted its application for listing on the Hong Kong Stock Exchange, with China International Capital Corporation as its sole sponsor. This marks the company's third attempt to list, following previous submissions in August 2022 and February 2025 [1] - Established in 2012, Real Bio focuses on the innovative research and development of drugs for viral infections, tumors, and cardiovascular diseases. The company has developed a comprehensive drug pipeline, including five candidate drugs [4][5] Product Pipeline - The core product, Azvudine, has received conditional approval in China for the treatment of HIV and COVID-19. The company is developing monotherapy and combination therapies for various cancers and HIV [4][5] - Other key products include CL-197 for long-term HIV treatment, Doshitini for non-small cell lung cancer, ZSSW-136 for malignant tumors, and MTB-1806 for acute ischemic stroke [4][5] Production and Commercialization - Real Bio has established its own production facilities with an annual capacity of approximately 3 billion tablets, certified by GMP, to meet commercialization needs. The company has a professional commercialization team and a comprehensive management system [6] - Azvudine was included in the National Reimbursement Drug List (NRDL) in 2023 and successfully renewed its status in 2024, ensuring price stability and broad market access [6] Financial Performance - For the fiscal year ending December 31, 2023, the company reported revenues of 344.21 million RMB, with a gross loss of 329.41 million RMB. The majority of revenue was derived from Azvudine, with significant R&D expenses impacting profitability [8][9][11] - The company recorded a net loss of 783.58 million RMB for 2023, primarily due to high R&D costs and administrative expenses [11] Market Overview - The global antiviral drug market was valued at $73.6 billion in 2023, with a projected compound annual growth rate (CAGR) of 6.3% from 2023 to 2030. The Chinese antiviral drug market is expected to grow from $7.8 billion in 2023 to $21.8 billion by 2030, with a CAGR of 15.8% [12][14] - The global HIV drug market reached $43.1 billion in 2023, with a projected CAGR of 4.1% through 2030. In China, the HIV drug market is expected to grow from $636.2 million in 2023 to $2.33 billion by 2030, with a CAGR of 20.4% [16][17] Board and Shareholding Structure - The board of directors consists of eight members, including three executive directors and three independent non-executive directors, responsible for overall management and strategic direction [25] - The founder, Wang Chaoyang, holds a combined 48.12% stake in the company through various investment vehicles [28][30]

Core Viewpoint - Real Bio Technology Co., Ltd. has submitted its application for listing on the Hong Kong Stock Exchange for the third time, with China International Capital Corporation as its sole sponsor [1]. Company Overview - Real Bio, established in 2012, focuses on the innovative research and development of drugs for viral infections, tumors, and cardiovascular diseases. The company has developed a comprehensive drug portfolio, including five candidate drugs, with its core product, Azvudine, conditionally approved in China for treating HIV and COVID-19 [5][6]. Product Pipeline - The core product Azvudine is a Class 1 innovative drug that received conditional approval from the National Medical Products Administration (NMPA) for HIV treatment in July 2021 and for COVID-19 in July 2022. It is the first oral antiviral drug developed by a Chinese company approved for COVID-19 treatment [6]. - The company also has a strong pipeline for cancer treatment, with Azvudine showing broad-spectrum anti-tumor activity and being the only nucleoside anti-tumor drug with dual mechanisms and high selectivity in the past 30 years [6]. Production and Commercialization - Real Bio has established its own production facilities with an annual capacity of approximately 3 billion tablets, certified by GMP, to meet existing commercialization needs. The company has a professional commercialization team and a complete management system [7]. - Azvudine was included in the National Reimbursement Drug List (NRDL) in 2023 and successfully renewed its inclusion in 2024, ensuring price stability and broad market access [7]. Financial Performance - The company reported revenues of RMB 344.21 million, RMB 237.87 million, and RMB 16.53 million for the fiscal years ending December 31, 2023, 2024, and the six months ending June 30, 2025, respectively. All revenue during the reporting period came from Azvudine [11]. - The company recorded a gross loss of RMB 329.41 million, a gross profit of RMB 164.85 million, and a gross loss of RMB 43.42 million for the same periods [12]. - The net losses for the fiscal years were RMB 783.58 million, RMB 40.04 million, and RMB 165.43 million, primarily due to significant R&D expenses for core products and other candidates [13]. Market Overview - The global antiviral drug market was valued at USD 73.6 billion in 2023, with a compound annual growth rate (CAGR) of 6.3% from 2018 to 2023, expected to reach USD 101.1 billion by 2030 [14]. - The Chinese antiviral drug market grew from USD 3.5 billion in 2018 to USD 7.8 billion in 2023, with a CAGR of 17.1%, projected to reach USD 21.8 billion by 2030 [16]. HIV Drug Market - The global HIV drug market increased from USD 35.3 billion in 2018 to USD 43.1 billion in 2023, with a CAGR of 4.1%, expected to reach USD 59.5 billion by 2030 [20]. - In China, the HIV drug market grew from USD 304.5 million in 2018 to USD 636.2 million in 2023, with a CAGR of 15.9%, projected to reach USD 2.33 billion by 2030 [21]. Oncology Drug Market - The global oncology drug market expanded from USD 128.1 billion in 2018 to USD 228.9 billion in 2023, with a CAGR of 12.3%, expected to reach USD 419.8 billion by 2030 [25]. - The Chinese oncology drug market increased from USD 23.8 billion in 2023 to USD 34.1 billion, with a CAGR of 7.2%, projected to reach USD 77.5 billion by 2030 [28].

Core Insights - Gilead showcased its commitment to health innovation at the China International Import Expo, presenting two significant products: the long-acting HIV pre-exposure prophylaxis drug Lenacapavir and the new drug for primary biliary cholangitis (PBC), Seladelpar [1][2][3] Product Highlights - Lenacapavir is a long-acting HIV capsid inhibitor that requires administration only twice a year, demonstrating over 99.9% efficacy in preventing HIV in global Phase III clinical trials [2] - Seladelpar is an innovative drug for PBC, a chronic autoimmune liver disease, which was approved in August 2023 and is the first therapy to improve biochemical markers and alleviate itching symptoms in PBC patients [3] Market Impact - Gilead has launched 13 innovative drugs in China, benefiting approximately 1.8 million patients, and aims to deepen its local strategy while enhancing drug accessibility and health equity [4] Collaborative Efforts - Gilead is actively pursuing collaborations to support the "Healthy China 2030" initiative, focusing on improving public health through academic exchanges, enhancing treatment capabilities in rural areas, and expanding innovative partnerships in oncology [6]

Core Insights - Gilead showcased two significant products at the China International Import Expo: the long-acting HIV pre-exposure prophylaxis drug Lenacapavir and the new drug for primary biliary cholangitis (PBC) Seladelpar, emphasizing its commitment to creating a healthier world [1][3] Product Highlights - Lenacapavir is a groundbreaking long-acting HIV capsid inhibitor that requires administration only twice a year, demonstrating over 99.9% efficacy in preventing HIV in global Phase III clinical trials [3][4] - Seladelpar is the first innovative therapy that improves biochemical markers and alleviates itching symptoms for PBC patients, which was included in the National Health Commission's list of rare diseases in 2023 [4] Market Entry and Approval - Lenacapavir received approval for HIV pre-exposure prophylaxis in Hainan Boao Lecheng International Medical Tourism Pilot Zone, almost simultaneously with FDA approval, marking a significant milestone for domestic drug approval processes [4] - Seladelpar was approved in Beijing under the urgent clinical need policy, providing new treatment hope for PBC patients in China [4] R&D Initiatives - Gilead is actively advancing local R&D with 16 ongoing projects in China, including 10 in oncology and 6 in non-oncology, aiming for synchronized global development to benefit Chinese patients [5] Access to Innovative Medicines - Over the past eight years, Gilead has launched 13 global innovative drugs in China, benefiting approximately 1.8 million patients, including notable products for HIV treatment and hepatitis [8] - The company emphasizes collaboration with various sectors to enhance access to innovative medicines and promote health equity [9]

Core Insights - Gilead Sciences' stock price dropped by 3.70% on November 7, attracting significant investor attention, despite the company's strong focus on innovation and development in the healthcare sector [1][2] - At the 8th China International Import Expo, Gilead showcased several innovative drugs, including the long-acting HIV pre-exposure prophylaxis drug Lenacapavir and the new drug Seladelpar for primary biliary cholangitis, highlighting its robust R&D capabilities [1] - Lenacapavir, as a first-in-class drug, requires only two doses per year and has demonstrated over 99.9% efficacy in global Phase III clinical trials, earning multiple international accolades [1] - Seladelpar is the first global innovative therapy that can simultaneously improve biochemical markers and alleviate pruritus symptoms in patients with primary biliary cholangitis, entering the Chinese market rapidly due to expedited drug review processes and favorable policies [1] Market Strategy - Gilead Sciences has made significant breakthroughs in introducing innovative drugs and actively integrates into the Chinese market through localized R&D strategies, conducting 16 clinical studies in China, many of which align with global timelines, particularly in oncology [2] - The company's commitment to the Chinese market is reflected in its plans to sign nearly ten collaborative projects to enhance the accessibility of innovative drugs and promote standardized treatment practices [2] - This proactive strategy not only boosts the company's market competitiveness but also contributes to the achievement of the "Healthy China 2030" goal [2] Long-term Outlook - Despite short-term stock price fluctuations causing market pressure, Gilead Sciences' ongoing innovation and strategic collaborations demonstrate long-term growth potential, instilling confidence in investors [2] - Investors are encouraged to monitor the company's movements in the Chinese market and its deep collaborations with partners to seize future investment opportunities [2] - Diversifying risks and maintaining a long-term perspective may be effective strategies for investing in such innovative companies [2]

Investment Rating - The report suggests a cautious subscription for the company [2]. Core Insights - The company is engaged in innovative drug research and development, manufacturing, and sales, with a focus on a unique EGFR×HER3 bispecific antibody ADC that is currently in Phase III clinical development [2]. - The company has established a robust ADC drug development platform, successfully advancing 10 candidate drugs into clinical stages and conducting approximately 70 clinical studies [2][3]. - The global ADC market is projected to grow significantly, reaching USD 13.5 billion in 2024 and USD 150.2 billion by 2033, with notable growth expected in both the Chinese and U.S. markets [3]. - The company's revenue is expected to show substantial growth, with a forecasted increase from HKD 701.8 million in 2022 to HKD 5.8 billion in 2024, representing a year-on-year growth of 1,033% [3]. - The company reported a loss of HKD 289.1 million in 2022, which increased to HKD 769.0 million in 2023, but is projected to turn profitable in 2024 with earnings of HKD 3.98 billion [3]. Summary by Sections IPO Details - The company plans to raise HKD 3.017 billion through its IPO, with a share price range of HKD 347.5 to HKD 389 [1]. - The total number of shares available for subscription is 8.63 million, with 90% allocated for international placement and 10% for public offering [1]. Financial Performance - The company’s revenue is projected to grow significantly from HKD 701.8 million in 2022 to HKD 5.8 billion in 2024, with a 40% year-on-year increase in the first half of 2025 [3]. - The company is expected to turn profitable in 2024 after reporting losses in previous years [3].

Core Insights - Gilead Sciences showcased multiple products at the 8th China International Import Expo, including two Asia debut products: long-acting HIV pre-exposure prophylaxis drug Lenacapavir and a new drug for primary biliary cholangitis (PBC) named Seladelpar [1][2] Group 1: Lenacapavir - Lenacapavir is a globally first-of-its-kind long-acting HIV capsid inhibitor that requires administration only twice a year, demonstrating over 99.9% effectiveness in preventing HIV based on global Phase III clinical studies [1] - Lenacapavir has received several prestigious recognitions, including being ranked first in Science magazine's "Top 10 Scientific Breakthroughs of 2024" and being included in Time magazine's "Best Inventions of 2025" [1] - The drug was approved for HIV pre-exposure prophylaxis in Hainan Boao Lecheng International Medical Tourism Pilot Zone in late June, almost simultaneously with the approval from the U.S. FDA [1] Group 2: Seladelpar - Seladelpar is an innovative drug targeting patients with primary biliary cholangitis, a chronic autoimmune liver disease recognized as a "silent killer" and included in the National Health Commission's list of rare diseases in 2023 [2] - The drug is the first global therapy that can improve biochemical indicators in PBC patients while alleviating itching symptoms, which significantly impact the quality of life [2] - Seladelpar was approved in August under Beijing's clinical urgent import policy, marking a significant step in addressing the needs of PBC patients [2] Group 3: Gilead's Market Presence - Gilead Sciences has launched 13 global innovative drugs in China over the past eight years, benefiting approximately 1.8 million patients [2] - At the expo, Gilead plans to deepen collaborations with various parties to enhance the accessibility of innovative drugs and promote standardized diagnosis and treatment [2]

Core Viewpoint - Bailitianheng (02615) has announced the launch of its H-share global public offering and plans to list on the Hong Kong Stock Exchange, marking a significant addition to the biotech sector in Hong Kong [1]. Group 1: H-share Offering Details - The base number of shares for the global offering is set at 8,634,300 shares, with 863,500 shares (approximately 10%) allocated for public offering in Hong Kong and 7,770,800 shares (approximately 90%) for international offering [1]. - The initial price range for the shares is determined to be between HKD 347.50 and HKD 389.00 [1]. - Bailitianheng's H-shares are expected to be eligible for inclusion in the Stock Connect program on the listing date [1]. Group 2: Company Overview - Bailitianheng focuses on cutting-edge biopharmaceuticals, addressing unmet clinical needs, particularly in the field of tumor macromolecule therapy, and aims to achieve global commercialization capabilities by 2029 [2]. - The company has established R&D centers in the U.S. and China, responsible for early product development and subsequent clinical research [2]. - Bailitianheng has developed a leading innovative drug R&D platform with global rights and complete intellectual property, including the HIRE-ADC platform and GNC platform [2]. Group 3: Clinical Development and Pipeline - The company has successfully developed three Phase III clinical assets (two ADC drugs and one bispecific antibody) and 14 early-stage core clinical assets [2]. - Bailitianheng is conducting nearly 90 clinical trials globally, including 15 Phase III studies in China and 10 in the U.S. [2]. Group 4: Strategic Collaborations and Financials - Bailitianheng has entered a strategic partnership with Bristol-Myers Squibb (BMS), involving an upfront payment of USD 800 million and a potential total deal value of up to USD 8.4 billion [4]. - The company has received the upfront payment and anticipates additional payments based on the success of ongoing clinical trials [4].

Core Viewpoint - Bailitianheng (02615) has announced the launch of its H-share global public offering and plans to list on the Hong Kong Stock Exchange, marking a significant addition to the biotech sector in Hong Kong [1]. Group 1: H-share Offering Details - The base number of shares for the global offering is set at 8,634,300 shares, with 863,500 shares allocated for public offering in Hong Kong, accounting for approximately 10% of the total offering, and 7,770,800 shares for international offering, accounting for about 90% [1]. - The price range for the offering is preliminarily set between HKD 347.50 and HKD 389.00 [1]. - Bailitianheng's H-shares are expected to be eligible for inclusion in the Stock Connect program on the listing date [1]. - The offering has garnered support from major underwriters including Goldman Sachs, JPMorgan, and CITIC Securities, along with interest from notable cornerstone investors such as Bristol-Myers Squibb (BMS) [1]. Group 2: Company Overview and R&D Capabilities - Bailitianheng focuses on addressing unmet clinical needs in the global biopharmaceutical frontier, particularly in the field of tumor macromolecule therapy, and aims to establish comprehensive commercialization capabilities by 2029 [2]. - The company has established R&D centers in both the U.S. and China, responsible for early product development and subsequent clinical research [2]. - Bailitianheng has developed a leading innovative drug R&D platform with global rights and complete intellectual property, including the HIRE-ADC platform and GNC platform [2]. - The company has successfully developed three Phase III clinical assets and 14 early-stage core clinical assets, with nearly 90 clinical trials ongoing globally [2]. Group 3: Key Products and Clinical Trials - The product "iza-bren" is a first-in-class dual-targeting antibody-drug conjugate (ADC) that has reached Phase III clinical trials, showing significant global clinical value and market potential [4]. - "iza-bren" has achieved its primary endpoint in a Phase III trial for nasopharyngeal carcinoma and is expected to be commercially available in China by 2025 [5]. - Bailitianheng has entered a strategic partnership with BMS, involving an upfront payment of USD 800 million and a potential total deal value of up to USD 8.4 billion, setting a record in the ADC field [5]. - Another promising drug, "T-Bren," targets HER2 and has demonstrated significant anti-tumor efficacy in clinical trials, positioning it as a best-in-class candidate [5].

Core Insights - The 8th China International Import Expo (CIIE) is being held from November 5 to 10 in Shanghai, showcasing 461 new products, technologies, and services, transforming into a global stage for innovation [1] Industry Highlights - The medical device and healthcare sector is highlighted as the most innovative, with major companies unveiling cutting-edge products, including Siemens Healthineers' brain-computer interface solution, which integrates advanced imaging and navigation technologies for surgical applications [3][5] - Sanofi's innovative drug, Trelagliptin, is the first to delay the progression of Type 1 diabetes, having received approval from China's National Medical Products Administration (NMPA) [5] - Abbott presents over ten innovative products, including cardiovascular and diabetes management solutions, emphasizing the importance of chronic disease management [7][9] - GSK introduces several groundbreaking products, including the first approved RSV vaccine and a long-acting treatment for chronic hepatitis B [9] - EssilorLuxottica showcases innovative products for vision health, including smart glasses and advanced myopia management solutions [10][19] Company Innovations - Skechers uses CIIE as a platform for launching new sports products, including various footwear models, demonstrating the brand's commitment to the Chinese market [20][22] - Ausnutria presents 61 products across six imported brands, focusing on innovative nutritional solutions for different life stages, including the launch of new probiotic products [23]